For women with BRCA1 gene mutations, fate always seems to draw a cruel multiple-choice question between "removing organs to prevent future diseases" and "preserving fertility but bearing a huge risk of cancer". At the end of 2025, Hollywood actress Angelina Jolie publicly displayed the scars left by removing the breast glands to prevent cancer, once again putting the plight of this group in the public eye. However, a ray of research from the field of biomedical engineering may completely rewrite the answer to this multiple-choice question. On January 28, 2026, the top international academic journal "Cell" reported on a major breakthrough made by Beihang University as the first completion unit in this field: a flexible implantable bioelectronic device called POCKET, which is expected to make "Julie" no longer face the desperate situation of "choosing one of the two".

In order to commend the advanced, set an example, and give full play to the exemplary role of advanced models and exemplary figures, the All-China Women's Federation decided to award Lan Zhen and 9 other people the title of National 38 Red Flag Bearer Pacesetter, Ruan Xiangyan and 598 others the title of National 38 Red Flag Bearer, 400 units including the Memorial Hall of the Chinese People's War of Resistance Against Japanese Aggression and the Ministry of Social Education, and 600 units including the Department of Otolaryngology, Head and Neck Surgery of Beijing Tongren Hospital Affiliated to Capital Medical University the title of National Women's Civilized Post.

On February 26, a 24-year-old woman from Xinjiang successfully gave birth to quintuplets in Wuhan. Medical data show that the birth probability of naturally conceived quintuplets in the world is only 1 in 60 million, which can be called the ultimate miracle of life.

Recently, the British medical community ushered in a historic breakthrough - a British woman gave birth to a baby after receiving a uterine transplant from a deceased donor. This is the first successful birth of a child in the UK through the "donation of the womb of the deceased".

Recently, a large-scale medical study completed in Hubei Province, China, showed that women collected menstrual blood at home for HPV testing, and its screening effect on cervical precancerous lesions was comparable to the current clinician sampling method in hospitals. This discovery provides a new path for cervical cancer screening to be more convenient and private.

Obstetrics and gynecology, as a key field to protect women's health and the birth of new life, has ushered in a series of breakthroughs between 2025 and 2026. From innovative drugs for hypertension in pregnancy, to new treatment strategies for endometriosis, to major breakthroughs in gynecological tumor immunotherapy and the deep integration of artificial intelligence (AI) in clinical applications, these cutting-edge studies not only bring new solutions to clinical practice, but also point out the direction for future medical development. This article will systematically review the recent key research results in the field of obstetrics and gynecology and explore their clinical significance and future prospects.

The field of endometriosis is undergoing a profound transformation from concept to practice. In 2025, the field of internal dysmorphosis will make systematic progress from pathogenesis to clinical diagnosis and treatment at three major international conferences (WCE, ACE, SEUD). Driven by the consensus of international conferences, its diagnosis and treatment model has fully shifted to patient-centered lifecycle management. Obstetrics and Gynecology Network specially invited Professor Xu Hong from the International Peace Maternal and Child Health Hospital Affiliated to Shanghai Jiao Tong University School of Medicine to conduct in-depth interpretation and outlook on core topics such as the new progress of the annual international conference, the "dual-track strategy" of the management of internal diseases and chronic diseases, and how China can enhance its international discourse.

As a common gynecological malignant tumor, the diagnosis and treatment strategy of endometrial cancer is undergoing profound changes with the advancement of molecular biology and immunotherapy. In 2025, a number of guidelines and clinical studies at home and abroad will further promote the precision and individualization of disease management. The Obstetrics and Gynecology Network is honored to invite Professor Cao Dongyan of Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences to sort out the important progress in the past year in the molecular stratification of early postoperative adjuvant treatment of endometrial cancer, the establishment of first-line standards for advanced immunization combined with chemotherapy, the expansion of the target immunity combined with "de-chemotherapy" model, and the exploration of back-line treatment for patients with refractory relapse.

In 2025, the field of Antibody-Drug Conjugates (ADCs) for gynecological tumors entered a critical period of target refinement and clinical translation. Vedetuximab was approved for the cervical cancer indication, while research on classic targets such as HER2 and FRα added significant new data. Breakthroughs were made in the exploration of novel targets, and domestic expert consensus was simultaneously established, marking the transition of this field from clinical exploration to standardized application. Obstetrics and Gynecology Network invited Professor Zhou Jinhua from the First Affiliated Hospital of Soochow University to systematically review the year's core progress and look ahead to the future direction of the field from three dimensions: the development history of ADCs, target exploration, and future innovations, providing professional reference for clinical diagnosis and treatment.

List of the 13th Committee of the CMA Society of Obstetrics and Gynaecology Released; Academician Zhu Lan Appointed Chairperson